The Pharma Data
AUGUST 16, 2021
Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV.
The Pharma Data
MAY 17, 2021
response in the over-50s, the age group deemed at higher risk for contracting the severe form of the virus. . The interim results from the phase 2 trial on the vaccine, published today, on the contrary, showed a “ strong neutralizing antibody response” ? First results are expected in the third quarter of 2021.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
APRIL 8, 2022
Now, new research from the Wyss Institute at Harvard University has revealed that this constant pattern of stretching and relaxing does even more – it generates immune responses against invading viruses. a Wyss Technology Development Fellow at the Institute. ” The results are published today in Nature Communications.
The Pharma Data
MARCH 13, 2022
People who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen’s omicron variant. The samples were stored after the researchers measured the T cell response. population.
The Pharma Data
NOVEMBER 10, 2020
Canadian biopharmaceutical company Medicago has announced that its investigational COVID-19 vaccine generated “significant antibody and cellular immune responses” after two doses in all subjects in an early-stage clinical trial. The interim analysis from the phase 1 trial has been published online at the preprint server, medRxiv.
Drug Target Review
AUGUST 11, 2023
In a new development, a recent paper published in Biology Methods & Protocols by Oxford University Press has highlighted a promising avenue for enhancing vaccine efficacy against infectious pathogens like the COVID-19 virus. The role of extracellular vesicles in COVID-19 virus infection [Internet]. Available from: [link]
The Pharma Data
AUGUST 24, 2020
They say genome sequencing shows the two strains of the virus are “clearly different”, making it the world’s first proven case of reinfection. Those infected develop an immune response as their bodies fight off the virus which helps to protect them against it returning.
Expert insights. Personalized for you.
52 
Let's personalize your content